Galectin 3 complements BNP in risk stratification in acute heart failure

Gregory J. FermannDepartment of Emergency Medicine, University of Cincinnati, Cincinnati, OH, USACorrespondence[email protected]

Christopher J. LindsellDepartment of Emergency Medicine, University of Cincinnati, Cincinnati, OH, USA

Alan B. StorrowDepartment of Emergency Medicine, Vanderbilt University, Nashville, TN, USA

Kimberly HartDepartment of Emergency Medicine, University of Cincinnati, Cincinnati, OH, USA

Matthew SperlingDepartment of Emergency Medicine, University of Cincinnati, Cincinnati, OH, USA

Susan RollDepartment of Emergency Medicine, University of Cincinnati, Cincinnati, OH, USA

Neal L. WeintraubDivision of Cardiovascular Diseases, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH, USA

Karen F. MillerDepartment of Emergency Medicine, Vanderbilt University, Nashville, TN, USA

David J. Maron

Allen J. NaftilanDivision of Cardiovascular Diseases, Department of Internal Medicine, Vanderbilt University, Nashville, TN, USA

John A. McphersonDivision of Cardiovascular Diseases, Department of Internal Medicine, Vanderbilt University, Nashville, TN, USA

Douglas B. SawyerDivision of Cardiovascular Diseases, Department of Internal Medicine, Vanderbilt University, Nashville, TN, USA

Robert ChristensonDepartment of Laboratory Medicine,University of Maryland, Baltimore, MD, USA

Sean P. CollinsDepartment of Emergency Medicine, Vanderbilt University, Nashville, TN, USA

show all

Abstract

Background: Galectin 3 (G3) is a mediator of fibrosis and remodeling in heart failure.

Methods: Patients diagnosed with and treated for Acute Heart Failure Syndromes were prospectively enrolled in the Decision Making in Acute Decompensated Heart Failure multicenter trial.

Results: Patients with a higher G3 had a history of renal disease, a lower heart rate and acute kidney injury. They also tended to have a history of HF and 30-day adverse events compared with B-type natriuretic peptide.

Conclusion: In Acute Heart Failure Syndromes, G3 levels do not provide prognostic value, but when used complementary to B-type natriuretic peptide, G3 is associated with renal dysfunction and may predict 30-day events.

Keywords::

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Galectin 3 complements BNP in risk stratification in acute heart failure

Information for

Open access

Opportunities

Help and information

Galectin 3 complements BNP in risk stratification in acute heart failure

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature